Polymedco Inc announced the direct availability of the BTA stat test from there sales force. The BTA stat test is a point of care technology for the early detection of recurrent bladder cancer. The test uses monoclonal antibodies to detect the presence of antigen associated with bladder tumor in urine. This is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. The specificity of the test was 93 - 95% in patients with cancers and non-genitourinary diseases and healthy individuals tested as part of a multi-center study. The test has a sensitivity which is considerably higher than voided urine cytology thus enabling detection of recurrent early stage and grade cancers which cytology often misses. The test requires three drops of urine and the results is delivered in five minutes. The appearance of a line in the patient window indicates a positive result. The test requires one voided urine sample with no sample preparation. The test is CLIA waived and available for prescription home use.